How is Immuno-Oncology
breaking barriers in cancer care?
- Immuno-oncology: An emerging field in cancer diagnosis and treatment
- Rapid advances in Immuno-oncology: Novel treatment combinations and newly identified targets
- Immuno-oncology: Therapies and challenges
- Diverse modalities in immunotherapy: mAbs, bifunctional agents, epigenetic modulators,vaccines, Adoptive-T-cell therapy, nanoparticles, oncolytic viruses and synthetic gene circuits.
- Immuno-oncology modalities for hard to treat tumors
- Adoptive T cell transfer (ATC) therapy
- Bispecific antibodies
- Immune checkpoint inhibitors and combination therapies
- Cancer vaccines
- Aurigene: Immuno-oncology services
About Aurigene
Aurigene Pharmaceutical Services Ltd. is a globally recognized contract research, development, and manufacturing organization (CDMO) that actively contributes to the advancement of pharmaceutical innovation. With a steadfast commitment to thought leadership, we offer comprehensive and integrated solutions to empower visionary companies in expediting their products from laboratory to market.
At Aurigene, we seamlessly blend our extensive knowledge, experience, and cutting-edge technology to catalyze the progress of our clients' groundbreaking endeavours. Our unwavering dedication to innovation is underscored by our world-class research and development centres in India, boasting a team of over 650 exceptional scientists. These centres are fortified by state-of-the-art commercial manufacturing facilities strategically located in India, the United Kingdom, Mexico, and the United States.
Fueling biologics advancements
with cutting-edge NBE services
Aurigene Pharmaceutical Services provides a wide range of high-quality and flexible scale development and manufacturing services for Biotherapeutics and Viral vectors. We are expanding our Biotherapeutics services, with a focus on mono-clonal antibodies(mAbs), therapeutic proteins and viral vectors. We are developing a facility which will meet the process development and clinical supplies needs of global biotech companies. The new facility is based on a state-of-the-art design concept, allowing maximum flexibility for a multi-product, multi-platform offering across proteins, mAbs, and viral vectors. We offer exclusive access to an established large-scale GMP manufacturing facility with a drug substance capacity of 15kl and fill-finish capabilities making it possible to provide commercial quantities seamlessly.
Share your details to download our whitepaper
You are about to leave Aurigene Pharmaceutical Services and affiliates website. Aurigene Pharmaceutical Services assumes no responsibility for the information presented on the external website or any further links from such sites. These links are presented to you only as a convenience, and the inclusion of any link does not imply endorsement by Aurigene Pharmaceutical Services.
If you wish to continue to this external website, click Proceed.
Leaving already?
Don't forget to join us at
CPHI Worldwide 2023.
October 24th-26th, 2023 | Barcelona, Spain
Get ready to accelerate your drug’s journey to the market